KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $30.0 million.

  • Nektar Therapeutics' Accumulated Expenses fell 11.68% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year decrease of 11.68%. This contributed to the annual value of $30.0 million for FY2024, which is 35.24% up from last year.
  • Nektar Therapeutics' Accumulated Expenses amounted to $30.0 million in FY2024, which was up 35.24% from $22.2 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Accumulated Expenses ranged from a high of $36.6 million in FY2022 and a low of $14.5 million during FY2020.
  • Over the past 3 years, Nektar Therapeutics' median Accumulated Expenses value was $30.0 million (recorded in 2024), while the average stood at $29.6 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Accumulated Expenses spiked by 132.33% in 2022, and later slumped by 39.38% in 2023.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Accumulated Expenses stood at $14.5 million in 2020, then climbed by 8.28% to $15.7 million in 2021, then soared by 132.33% to $36.6 million in 2022, then plummeted by 39.38% to $22.2 million in 2023, then skyrocketed by 35.24% to $30.0 million in 2024.